Novocure Reports Second Quarter 2018 Financial Results and Provides Company Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Novocure Reports Second Quarter 2018 Financial Results and Provides Company Update
July 27, 2018 8:44 AM EDT
Mizuho Securities raised its price target on NovoCure Ltd. (NASDAQ: NVCR) to $44.00 (from $32.00) while maintaining a Buy rating.
Analyst Difei Yang commented, "NovoCure reported 2Q18 results yesterday. Net revenue of $61.5 mil beat FactSet consensus of $59.5 mil while EPS of $(0.17) was slightly below consensus of... More
July 26, 2018 6:17 AM EDT
Novocure (NASDAQ: NVCR) reported Q2 EPS of ($0.17), $0.01 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $61.5 million versus the consensus estimate of $59.52 million.
In the second quarter of 2018, Novocure demonstrated continued commercial momentum for Optune and continued progress on key clinical development programs, noted Asaf Danziger, Novocures Chief Executive Officer. We delivered record quarterly revenue of $61.5 million, up 60 percent from the second quarter 2017 and 18... More
